Figure 3 |.

Eradication of bone marrow and blood CLL cells occurred in a patient treated with chemotherapy followed by anti-CD19 CAR T cells and IL-2. a | Before treatment almost all bone marrow CD19⁺ B-lineage cells also expressed CD5. Expression of CD5 together with CD19 is an aberrant phenotype that is typical for CLL. 14 months after treatment, the aberrant CD19⁺, CD5⁺ population is absent. b | Blood B cells, most of which were CLL cells, were eliminated after treatment. B cells, which were defined as CD19⁺ cells, were assayed by flow cytometry. The results are from patient 3 from Table 1. Abbreviations: CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukaemia; IL, interleukin. Reproduced with permission from American Society of Hematology © Kochenderfer, J. N. et al. Blood 119, 2709–2720 (2012).